Diagnosis of prostate cancer – fusion (targeted) biopsy
DOI: https://doi.org/10.22591/magyurol.2023.2.huttla.66
Authors:
Hüttl András dr.
Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography for prostate-cancer detection in men.
The author discusses the indication of MRI according to EAU recommendation, the challenges of visual/cognitive targeted biopsy (cog-MRGB), software-assisted MRI-transrectal ultrasound (TRUS) fusion biopsy (fus-MRGB), and direct in-bore MRI targeted biopsy (in-bore-MRGB).
High-level evidence demonstrates that mpMRI and targeted biopsy (MRGB) are able to increase the detection of clinically significant prostate cancer, while at the same time, decrease the detection of clinically insignificant prostate cancer.